^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JMT601

    i
    Other names: JMT601, CPO107
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    CD20 inhibitor, CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1/2, N=7, Suspended, Conjupro Biotherapeutics, Inc. | N=75 --> 7 | Recruiting --> Suspended
    Enrollment change • Trial suspension • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JMT601
    almost2years
    Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL) (ASH 2022)
    2010]CPO107 is a bispecific fusion protein based off the anti-CD20 ofatumumab antibody with one Fab fragment being replaced with a SIRPα domain, which natively binds CD47...The monoclonal antibody Magrolimab (Hu5F9-G4) in combination with rituximab induced a high rate of tolerable and durable complete responses in heavily pretreated patients (pts) with rituximab-refractory DLBCL and FL [Chao et al...Upon reaching the MTD or RP2D, Part B of the study will enroll approximately 15 pts with CD20+ NHL to explore preliminary efficacy. The study has been registered on ClinicalTrials.gov (NCT04853329).
    Clinical • P1/2 data • IO biomarker
    |
    CD19 (CD19 Molecule) • CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD20 expression • CD47 overexpression • CD47 expression
    |
    Rituxan (rituximab) • Arzerra (ofatumumab) • magrolimab (ONO-7913) • JMT601
    over2years
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Conjupro Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JMT601
    3years
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1/2, N=75, Not yet recruiting, Conjupro Biotherapeutics, Inc. | Initiation date: Aug 2021 --> Nov 2021 | Trial primary completion date: Aug 2024 --> Nov 2024
    Clinical • Trial initiation date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JMT601
    over3years
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1/2, N=75, Not yet recruiting, Conjupro Biotherapeutics, Inc.
    Clinical • New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JMT601